Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Profit After Tax (2016 - 2026)

Intellia Therapeutics has reported Profit After Tax over the past 12 years, most recently at -$96.2 million for Q1 2026.

  • Quarterly Profit After Tax rose 15.83% to -$96.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$394.6 million through Mar 2026, up 24.97% year-over-year, with the annual reading at -$412.7 million for FY2025, 20.49% up from the prior year.
  • Profit After Tax was -$96.2 million for Q1 2026 at Intellia Therapeutics, roughly flat from -$95.8 million in the prior quarter.
  • Over five years, Profit After Tax peaked at -$95.8 million in Q4 2025 and troughed at -$147.0 million in Q2 2024.
  • The 5-year median for Profit After Tax is -$113.4 million (2022), against an average of -$116.7 million.
  • Year-over-year, Profit After Tax tumbled 217.87% in 2022 and then soared 31.11% in 2025.
  • A 5-year view of Profit After Tax shows it stood at -$113.4 million in 2022, then dropped by 16.54% to -$132.2 million in 2023, then increased by 2.47% to -$128.9 million in 2024, then rose by 25.69% to -$95.8 million in 2025, then fell by 0.46% to -$96.2 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Profit After Tax are -$96.2 million (Q1 2026), -$95.8 million (Q4 2025), and -$101.3 million (Q3 2025).